GT Biopharma authorizes new convert preferred stock

GT Biopharma's board of directors authorized a new series of 10% convertible preferred stock, intended to be issued pursuant to a Purchase Agreement. This corporate action indicates financial maneuvering and potential capital strategy, as it authorizes issuance over a specific share volume.